A U.S. Patent for a "Regulatable Promoter" was awarded to Lonza on May 28th, 2019. The present invention is a method of producing a protein of interest (POI) by culturing a recombinant eukaryotic cell line com

Iovance Biotherapeutics announced this week that it will build a 136,000-square-foot facility in Philadelphia to produce cancer therapies using its tumor-infiltrating lymphocyte (TIL) technology. While construction will take about two years, the C

The rose may be one of the most iconic symbols of the fragility of love in popular culture, but now the flower could hold more than just symbolic value. A new device for collecting and purifying water, developed at The University of Texas at Austi

Ammonia has been reported to be toxic and inhibitory for mammalian cell cultures for many years. Reduction of growth rates and maximal cell densities in batch cultures, changes in metabolic rates, perturbation of protein processing and virus repli

Amarin will get a regulatory decision sooner than expected on an important label expansion for its fish oil-based pill, Vascepa. The company announced this week that the U.S. FDA will decide by September 28th on approving the drug for treating hea

Just a day after the announcement of his resignation from Atara comes word that Dietmar Berger has joined Sanofi as head of development. Berger spent almost 20 years rising through the oncology ranks at Amgen, Bayer and Genentech, culminating in h

A U.S. Patent for a "Method of Removing DNA from Biotechnological Products" was awarded to BASF on May 28th, 2019. The present invention relates to a method for degrading DNA in a sample obtained by microbial

AstraZeneca has decided to trim back its 2015 alliance with Inovio Pharmaceuticals, which focused on combining the biotech's DNA cancer vaccines with AZ's cancer immunotherapies. In an SEC filing, Inovio has revealed that AZ's Medimmune subsidiary

Atara Biotherapeutics has announced the appointment of Pascal Touchon as President, Chief Executive Officer and member of the Board of Directors. Prior to joining Atara, Dr. Touchon was most recently at Novartis Oncology serving as Global Head, Ce

Iovance Biotherapeutics announced this week that it will build a 136,000-square-foot facility in Philadelphia to produce cancer therapies using its tumor-infiltrating lymphocyte (TIL) technology. While construction will take about two years, the C

The U.S. FDA has approved a new way for cancer drugs to be approved more quickly. The approval for the breast cancer treatment Piqray in combination with fulvestrant and alongside a companion diagnostic - came more than three months ahead of its P

The U.S. FDA has approved a new way for cancer drugs to be approved more quickly. The approval for the breast cancer treatment Piqray in combination with fulvestrant and alongside a companion diagnostic - came more than three months ahead of its P

A U.S. Patent Application for an "Automated Bioprocess Development" was awarded to TAP on May 23rd, 2019. The present invention is a method for automating process development in a bioprocessing environment. The

The U.S. FDA has approved Zolgensma, the first gene therapy for a type of spinal muscular atrophy. The disease is caused by a defect in a gene that makes SMN, a protein necessary for the survival of motor neurons. Zolgensma uses a re-engineered vi

Aspen Brook is closed today so that we may observe Memorial Day here in the States with family and friends. The Alert will return tomorrow, Tuesday, May 28th, at its regular time.

While there are numerous bioprocess analyzers, each with its own strengths and weaknesses, the requirement that the instrument be well suited for not just manufacturing scale mammalian cell culture, but proven GMP compliance, greatly reduces the a

A U.S. Patent for a "Bioreactor with Condenser" was awarded to Sartorius Stedim on May 21st, 2019. The present invention is a bioreactor with a vessel having at least one gas dissipation duct for gas discharge

Chugai, a business unit of Roche, announced this week a decision to construct a centralized research laboratory. The new facility, to be known as the Chugai Life Science Park, is being constructed in Yokohama. The new facility will become home to

Researchers from the Hubrecht Institute and Radboud University have developed a human model in which they use organoids, or mini organs, to study the function of specific genes that are mutated in liver cancer. Using this method, they have found t

Scott Gottlieb, who recently stepped down as the head of the U.S. FDA, has rejoined venture capital firm New Enterprise Associates as a full-time investing partner. Gottlieb had been a venture partner with NEA for 10 years before President Trump t

After a four-year decline that erased 65% from the value of Sun Pharma, comes word that the world's biggest generic drug manufacture will pursue branded drugs. That won't be easy, especially when the multinationals that dominate the pharmaceutical

Scott Gottlieb, who recently stepped down as the head of the U.S. FDA, has rejoined venture capital firm New Enterprise Associates as a full-time investing partner. Gottlieb had been a venture partner with NEA for 10 years before President Trump t

Amgen this week agreed to buy Scandinavian biopharmaceutical company Nuevolution AB for $167 million to boost its position in drug discovery. Nuevolution has a patent protected drug research platform to identify small-molecule drug candidates to b

Chugai, a business unit of Roche, announced this week a decision to construct a centralized research laboratory. The new facility, to be known as the Chugai Life Science Park, is being constructed in Yokohama. The new facility will become home to

On the eve of its initial day of public stock trading, Dallas-based cancer drug developer Peloton Therapeutics was sold to biopharma giant Merck in a deal that could total $2.2 billion. Merck will pay $1.05 billion in cash now, plus $1.15 billion

A U.S. Patent for a "Flexible Manufacturing System" was awarded to Xoma on May 21st, 2019. The present invention is a unitary structure adapted to be disposed within a housing, comprising: at least one control